NCT02172131View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects

PHASE1TerminatedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

February 28, 2007

Conditions
Healthy
Interventions
DRUG

BI 1744 CL

DRUG

Placebo

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02172131 - Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects | Biotech Hunter | Biotech Hunter